European Patent Office Approves Patent For Indaptus Therapeutics' Platform Technology; Patent Titled 'Methods Of Treatment Of Infections Using Bacteria"
Portfolio Pulse from Benzinga Newsdesk
The European Patent Office has approved a patent for Indaptus Therapeutics' Decoy technology platform, titled 'Methods of Treatment of Infections Using Bacteria'. This patent provides protections for the technology's application in preventing or treating viral infections, alone or in combination with standard care. It is the second patent granted to Indaptus outside the United States for this application.
January 04, 2024 | 1:14 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Indaptus Therapeutics has been granted a European patent for its Decoy technology platform, which could enhance the company's intellectual property portfolio and potentially increase its market opportunities in Europe.
The approval of the patent by the European Patent Office is a positive development for Indaptus Therapeutics, as it strengthens the company's intellectual property rights and could lead to increased investor confidence. The patent approval may also facilitate potential partnerships or licensing deals in Europe, which could have a favorable impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100